Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Redvault Biosciences LP
Profile last edited on: 8/19/20      CAGE: 6ZWA9      UEI: RTNFR882TQP8

Business Identifier: Genomic and diagnostic technologies
Year Founded
2013
First Award
2016
Latest Award
2019
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

3900 Essex Lane Suite 1030
Houston, TX 77027
   (832) 831-8287
   reachus@redvaultbio.com
   www.redvaultbio.com
Location: Single
Congr. District: 07
County: Harris

Public Profile

Redvault Biosciences is structured around working on next-generation sequencing technologies to determine haplotypes and structural variation in complex genomes. With a focus on nucleic acid chemistries for novel sequencing strategies, the objective is to develop advanced diagnostic platforms for the early detection and monitoring of circulating disease biomarkers

Extent of SBIR involvement

User Avatar
Phase I Awards
3
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$520,555
Phase II Dollars
$99,970
Total Awarded
$620,525

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
15-19

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2019 1 NIH $223,895
Project Title: Solid-Phase Replication of Long Template Libraries for NGS Applications
2017 1 NIH $249,829
Project Title: Digital Analysis of Plasma miRNA populations in Pancreatic Cancer
2016 1 NIH $146,801
Project Title: Efficient Creation of Long-Template Libraries for Next-Generation Sequencing

Key People / Management

  Michael L Metzker -- Founder President and CEO

  Jill Tennill -- COO

  Christopher Weier

Company News

There are no news available.